소 및 돼지의 생식 질환 시장 : 제품별, 질병유형별, 동물유형별, 최종사용자별, 지역별 예측(-2029년)

The global cattle & porcine/swine reproductive diseases market is projected to reach USD 975.8 million by 2029 from USD 758.2 million in 2024 at a CAGR of 5.2%. Between January 2021 and August 2024, major players in this market adopted various strategies to expand their global presence and increase market share. These tactics include entering into strategic agreements, divestitures, expanding operations, and acquiring other companies. These efforts aim to enhance product portfolios, improve efficiency, and tap into new regional markets. The competitive landscape illustrates the industry's focus on meeting the rising demand for reproductive disease treatments in cattle and pigs, which is crucial for supporting the global livestock sector.

"The Pharmaceutical segment is expected to grow at the second highest CAGR in the cattle & porcine/swine reproductive diseases market."

By product type, the pharmaceuticals segment represents the second highest CAGR in the cattle & porcine/swine reproductive diseases market. This is mainly due to some crucial factors. Advancements in the manufacturing of vaccines, such as the development of more effective formulations and sustainable production practices, have a great influence on market growth. The demand for the above-mentioned pharmaceutical products has increased due to the growing incidence of reproductive diseases in farm animals. The development of diagnostic tools supplements the application of vaccines and antibiotics, enabling timely and efficient disease detection. These two innovations, along with other improvements in their efficacy, have strongly supported the top market position of the pharmaceuticals segment.

"Bovine Viral Diarrhea (BVD) segment witnessed the second-highest CAGR in the cattle & porcine/swine reproductive diseases market."

BVD is expected to be the second fastest-growing segment in terms of CAGR in the cattle & porcine/swine reproductive diseases market during the forecast period. Several factors have contributed to this growth: first, BVD affects several million cattle worldwide, resulting in marked economic losses due to reduced milk production and poor meat quality. Further, the various symptoms and complications of the disease necessitate a fitting response on the part of farmers and veterinarians. Increased regulatory focus, besides active initiatives by the industry for control and eradication of BVD, also drives the market. As such efforts start turning more concentrated and fruitful, solutions and services directed at overcoming BVD further amplify the demand for the same, thereby fueling market growth.

"The Porcine segment of the cattle & porcine/swine reproductive diseases market accounted for the second largest market share."

Based on animal type, the porcine segment accounted for the second largest market share in the cattle & porcine/swine reproductive diseases market because of high economic impact of diseases like Porcine Reproductive and Respiratory Syndrome (PRRS) on pig farms drives significant spending on management and prevention. Second, the global rise in pork consumption and intensive pig farming practices increase the risk of disease spread, highlighting the need for effective disease control. Lastly, ongoing research works in vaccine and treatment options for porcine diseases boost market growth by offering better solutions to manage and prevent outbreaks. As pork production continues to expand, the focus on controlling reproductive diseases in pigs remains a high priority, further driving market demand.

"Veterinary hospitals and clinics segment of the cattle & porcine/swine reproductive diseases market is expected to witness the second highest CAGR."

By end user, veterinary hospitals & clinics are expected to record the second-highest CAGR in the cattle & porcine/swine reproductive diseases market during the forecast period. Several factors contribute to such significant growth. Veterinary hospitals & clinics provide a place of advanced diagnostics and treatments essential for such specialized care, especially in reproductive problems in livestock. Due to this realization, farmers view these facilities as a source of expert medical services, thus making them seek accurate disease detection and a definite treatment plan. Besides this, increasing awareness concerning regular visits to veterinary institutes has also made farmers rely more on such institutions for preventive as well as curative purposes. The quality and customized services offered by veterinary clinics and hospitals contribute considerably to their popularity in the market.

"North America is expected to have the second highest CAGR in the cattle & porcine/swine reproductive diseases market, in the forecast period."

In the North America region, the cattle & porcine/swine reproductive diseases market has grown significantly. The region's extensive cattle and pig farms drive a significant demand for reproductive health products and services. This demand is supported by well-established veterinary research institutions that foster innovation and advancements in disease management. Furthermore, strong government support and funding for animal health initiatives in countries such as the US and Canada enhance the market's robustness. The emphasis on boosting livestock productivity and upholding high standards of animal welfare also strengthens the region's position in the global market.

A breakdown of the primary participants (supply side) for the cattle & porcine/swine reproductive diseases market referred to for this report is provided below:

• By Company Type: Tier 1-45%, Tier 2-20%, and Tier 3-35%
• By Designation: C-level-35%, Director Level-25%, and Others-40%
• By Region: North America-40%, Europe-20%, Asia Pacific-25%, Latin America-10%, and Middle East & Africa-5%

A breakdown of the primary participants (demand side) for the cattle & porcine/swine reproductive diseases market refer to for the report is provided below:

• By End User Type: Cattle and Porcine Farms-55%, Veterinary Hospitals and Clinics-30%, and Veterinary Reference Laboratory-15%
• By Designation: Veterinarians-45%, Farm Owners-40%, and Laboratory Technicians-15%
• By Region: North America-34%, Europe-27%, Asia Pacific-23%, Latin America-9%, and Middle East & Africa-7%

Key Market Players:

The prominent players in the cattle & porcine/swine reproductive diseases market include Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmBH (Germany), Virbac (France), Elanco Animal Health Incorporated (US), Vetoquinol S.A. (France), Ceva Sante Animale (France), Idexx Laboratories (US), Thermo Fisher Scientific Inc. (US), Biochek Smart Veterinary Diagnostics (Netherlands), Ring Biotechnology Co Ltd. (China), Sequent Scientific Limited (India), Hipra (Spain), Qiagen N.V. (Germany), Innovative Diagnostics (France), Colorado Serum Company (US), Indian Immunologicals Ltd (US), Refit Animal Care (India), Calier (US), Megacor Diagnostik GmBH (Austria), Vetanco (Brazil), Biogenesis Bago (Argentina), Advacare Pharma (US), Bio-X Diagnostics S.A. (Belgium), Pax Healthcare (India).

Research Coverage:

The market analysis examines the cattle & porcine/swine reproductive diseases market in numerous segments. It seeks to estimate the market size and growth potential across many segments, including product type, disease type, animal type, end user type and geography. The study also includes a detailed competitive analysis of the market's top competitors, as well as company profiles, significant insights about their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The study will assist industry leaders/new entrants in this market by providing information on the closest approximations of the cattle & porcine/swine reproductive diseases market and its segments. This research will assist stakeholders understand the competitive landscape, obtaining insights to better position their firms, and developing appropriate go-to-market strategies. The study will also assist stakeholders in understanding the market pulse and obtaining information on major market drivers, constraints, opportunities, and challenges.

This report provides insights into the following pointers:

• Analysis of key Drivers: Drivers (Rising demand for animal-derived food products, Increasing prevalence of reproductive health issues, Growing number of veterinary practitioner in developed markets, Increasing per capita income of farmers in developing countries), Restrains (Lack of awareness and knowledge among small-scale farmers), Opportunities (Advancements in veterinary healthcare, Untapped emerging markets), Challenges (Stringent regulatory guidelines for livestock industry) influencing the growth of the cattle & porcine/swine reproductive diseases market.
• Market Penetration: Comprehensive information on the product portfolios of the leading companies in the cattle & porcine/swine reproductive diseases market. The report breaks down the market by product type, disease type, animal type, end user type and region.
• Product Enhancement/Innovation: Detailed information about forthcoming trends and product launches in the cattle & porcine/swine reproductive diseases market.
• Market Development: Comprehensive data on attractive rising markets broken down by product type, disease type, animal type, end user type and region.
• Market Diversification: Comprehensive information on new products, expanding geographies, current advancements, and investments in the cattle & porcine/swine reproductive diseases market.
• Competitive Assessment: In-depth analysis of market share, growth strategies, product and service offerings, and capabilities of the main udder health products manufacturers.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.2.2 MARKETS COVERED
  • 1.2.3 YEARS CONSIDERED
  • 1.2.4 CURRENCY CONSIDERED
• 1.3 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
  • 2.4.1 STUDY ASSUMPTIONS
• 2.5 RISK ASSESSMENT
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET OVERVIEW
• 4.2 EUROPE: CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY PRODUCT AND COUNTRY (2023)
• 4.3 REGIONAL MIX: CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET
• 4.4 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for animal-derived food products
    • 5.2.1.2 Increasing prevalence of reproductive health issues
    • 5.2.1.3 Rising number of veterinary practitioners in developed markets
    • 5.2.1.4 Increasing per capita income of farmers in emerging markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Limited awareness & education among small-scale farmers
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Advancements in veterinary healthcare
    • 5.2.3.2 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory guidelines for livestock industry
• 5.3 INDUSTRY TRENDS
  • 5.3.1 INCREASING ADOPTION OF VACCINATION PROGRAMS
  • 5.3.2 EMPHASIS ON SUSTAINABLE PRACTICES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Vaccination technologies
    • 5.4.1.2 Diagnostic tools
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Genomic selection & breeding
    • 5.4.2.2 Precision livestock farming
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Nutritional supplements & additives
    • 5.4.3.2 Integration of livestock management software
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 BARGAINING POWER OF SUPPLIERS
  • 5.5.3 BARGAINING POWER OF BUYERS
  • 5.5.4 THREAT OF SUBSTITUTES
  • 5.5.5 COMPETITIVE RIVALRY
• 5.6 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.6.2 BUYING CRITERIA
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 REGULATORY ANALYSIS
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 PATENT ANALYSIS
  • 5.8.1 PATENT PUBLICATION TRENDS FOR CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET
  • 5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.9 TRADE ANALYSIS
  • 5.9.1 TRADE ANALYSIS FOR CATTLE & PORCINE REPRODUCTIVE PRODUCTS
• 5.10 PRICING ANALYSIS
  • 5.10.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE
  • 5.10.2 AVERAGE SELLING PRICE TREND OF CATTLE & PORCINE REPRODUCTIVE HEALTH PRODUCTS, BY REGION
• 5.11 REIMBURSEMENT ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS IN CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET
• 5.14 IMPACT OF GEN AI ON CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 INNOVATION IN BOVINE REPRODUCTIVE DISEASE VACCINATION
  • 5.16.2 TECH-DRIVEN SOLUTIONS FOR LIVESTOCK REPRODUCTIVE HEALTH
  • 5.16.3 INTEGRATED HEALTH SOLUTIONS FOR CATTLE REPRODUCTIVE HEALTH
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 VALUE CHAIN ANALYSIS
• 5.19 ADJACENT MARKETS FOR CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET
• 5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESSES
• 5.21 INVESTMENT & FUNDING SCENARIO

6 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 DIAGNOSTICS
  • 6.2.1 ELISA TEST KITS
    • 6.2.1.1 Advancements in biotechnology to drive market
  • 6.2.2 PCR TEST KITS
    • 6.2.2.1 Increasing adoption of on-farm PCR testing solutions to fuel uptake
  • 6.2.3 RAPID ANTIGEN TEST KITS
    • 6.2.3.1 Growing demand for reliable solutions with quick turnaround time to drive market
  • 6.2.4 OTHER DIAGNOSTIC PRODUCTS
• 6.3 PHARMACEUTICALS
  • 6.3.1 VACCINES
    • 6.3.1.1 Enhancements in vaccine technology & formulation to drive market
  • 6.3.2 ANTIBIOTICS
    • 6.3.2.1 Convenient purchase options and long-term benefits to boost demand
  • 6.3.3 HORMONAL THERAPY
    • 6.3.3.1 Ability to mimic natural hormones to boost demand
  • 6.3.4 OTHER PHARMACEUTICAL PRODUCTS
• 6.4 SUPPLEMENTS
  • 6.4.1 VITAMINS & MINERALS
    • 6.4.1.1 Rising focus on nutrition and reproductive health to support market growth
  • 6.4.2 OTHER SUPPLEMENTS

7 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY DISEASE TYPE

• 7.1 INTRODUCTION
• 7.2 LEPTOSPIROSIS
  • 7.2.1 RISING CASES DUE TO CLIMATE CHANGE TO DRIVE MARKET
• 7.3 BRUCELLOSIS
  • 7.3.1 IMPACT ON LIVESTOCK PRODUCTIVITY DUE TO CONTAGIOUS NATURE TO SUPPORT MARKET GROWTH
• 7.4 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS)
  • 7.4.1 INCREASING PORK CONSUMPTION TO PROPEL MARKET
• 7.5 BOVINE VIRAL DIARRHEA (BVD)
  • 7.5.1 HIGH MORBIDITY RATE TO DRIVE MARKET
• 7.6 VIBRIOSIS
  • 7.6.1 GROWING DEMAND FOR HIGH-YIELDING LIVESTOCK TO SUPPORT MARKET GROWTH
• 7.7 OTHER CATTLE & PORCINE DISEASES

8 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY ANIMAL TYPE

• 8.1 INTRODUCTION
• 8.2 CATTLE
  • 8.2.1 DAIRY CATTLE
    • 8.2.1.1 Increasing demand for milk & dairy products to boost demand
  • 8.2.2 BEEF CATTLE
    • 8.2.2.1 Increasing demand for beef to drive market
• 8.3 PORCINE

9 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 CATTLE & PORCINE FARMS
  • 9.2.1 GROWING DEMAND FOR MEAT & DAIRY PRODUCTS TO DRIVE MARKET
• 9.3 VETERINARY HOSPITALS & CLINICS
  • 9.3.1 INCREASING VETERINARY HEALTHCARE INVESTMENTS IN EMERGING MARKETS TO BOOST DEMAND
• 9.4 VETERINARY REFERENCE LABORATORIES
  • 9.4.1 INCREASING TECHNOLOGICAL ADVANCEMENTS IN VETERINARY DIAGNOSTICS TO SUPPORT MARKET GROWTH

10 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Large-scale livestock operations and advanced veterinary practices to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Rising concerns about food safety & quality to fuel market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Adoption of advanced technologies for milk & dairy products to drive market
  • 10.3.3 UK
    • 10.3.3.1 Favorable government support for animal healthcare to boost demand
  • 10.3.4 FRANCE
    • 10.3.4.1 Growth in veterinary & healthcare industries to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Growing focus on swine & dairy farming to fuel uptake
  • 10.3.6 SWITZERLAND
    • 10.3.6.1 Technologically advanced agriculture sector to fuel market
  • 10.3.7 SPAIN
    • 10.3.7.1 High exports of meat & milk to contribute to market growth
  • 10.3.8 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Rising focus on dairy industry to drive market
  • 10.4.3 CHINA
    • 10.4.3.1 Rising prevalence of infectious diseases in livestock to propel market
  • 10.4.4 INDIA
    • 10.4.4.1 Expanding cattle population to boost demand
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Emphasis on sustainable & systematic farming practices to support market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Rise in pork & beef consumption to drive market
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Growing demand for veterinary services to fuel uptake
  • 10.5.3 MEXICO
    • 10.5.3.1 Improvements in animal welfare to support market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Growing demand for dairy to fuel market
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
  • 11.4.1 RANKING OF KEY MARKET PLAYERS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Product footprint
    • 11.5.5.3 Disease type footprint
    • 11.5.5.4 Animal type footprint
    • 11.5.5.5 End-user footprint
    • 11.5.5.6 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 DYNAMIC COMPANIES
  • 11.6.3 STARTING BLOCKS
  • 11.6.4 RESPONSIVE COMPANIES
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 COMPANY VALUATION
  • 11.7.2 FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 R&D EXPENDITURE OF KEY PLAYERS
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT APPROVALS/LAUNCHES
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS
  • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 ZOETIS INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
      • 12.1.1.3.2 Expansions
      • 12.1.1.3.3 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 MERCK & CO., INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
      • 12.1.2.3.2 Other developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 VIRBAC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
      • 12.1.4.3.2 Expansions
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 ELANCO ANIMAL HEALTH INCORPORATED
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
      • 12.1.5.3.2 Expansions
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 VETOQUINOL S.A.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 CEVA SANTE ANIMALE
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 IDEXX LABORATORIES, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Other developments
  • 12.1.9 THERMO FISHER SCIENTIFIC INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 BIOCHEK SMART VETERINARY DIAGNOSTICS
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Expansions
  • 12.1.11 RING BIOTECHNOLOGY CO LTD.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches & approvals
  • 12.1.12 SEQUENT SCIENTIFIC LIMITED
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 HIPRA
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 QIAGEN N.V.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 INNOVATIVE DIAGNOSTICS
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Other developments
• 12.2 OTHER PLAYERS
  • 12.2.1 COLORADO SERUM COMPANY
  • 12.2.2 INDIAN IMMUNOLOGICALS LTD.
  • 12.2.3 REFIT ANIMAL CARE
  • 12.2.4 CALIER
  • 12.2.5 MEGACOR DIAGNOSTIK GMBH
  • 12.2.6 VETANCO
  • 12.2.7 BIOGENESIS BAGO
  • 12.2.8 ADVACARE PHARMA
  • 12.2.9 BIO-X DIAGNOSTICS S.A.
  • 12.2.10 PAX HEALTHCARE

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS